GlaxoSmithKline said it has applied for FDA approval for its Fluarix flu vaccine, appealing to the agency to allow it to supply the U.S. market, where there is expected to be another shortage of the shots in the next season. GSK already markets Fluarix in more than 75 other countries, but said it could provide as many as 10 million shots for the U.S. market if the FDA gives its approval.

Full Story:

Related Summaries